glp-1 drugs and breast cancer Glucagon-like peptide 1 receptor agonists risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research Ending Breast Cancer Forever |

This peptide, which they named 'exendin-4', not only stimulated insulin secretion in the same way as GLP-1 but also had the advantage that it remained active for more than two hours after subcutaneous injection

doi: 10.1136/ard-2023-224762

Projected Prevalence of Obesity in Primary Total Knee Arthroplasty: How Big Will the Problem Get

Only 4 of the 30 people regained weight and chose to return to weekly dosing

When S tu is low (indicating a significant penalty for halting treatment), the effectiveness of various heuristic approaches compared to the optimal policy decreases as supply uncertainty grows

The FDAs action also opened a door for Medicare coverage in patients with cardiovascular disease an early sign that access for these expensive medicines could expand beyond the well-insured